Design Therapeutics 관리
관리 기준 확인 2/4
Design Therapeutics' CEO is Pratik Shah, appointed in Aug 2023, has a tenure of 1.25 years. total yearly compensation is $6.32M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $675.59K. The average tenure of the management team and the board of directors is 3.2 years and 4 years respectively.
주요 정보
Pratik Shah
최고 경영자
US$6.3m
총 보상
| CEO 급여 비율 | 5.7% |
| CEO 임기 | 1.3yrs |
| CEO 소유권 | 0.2% |
| 경영진 평균 재임 기간 | 3.2yrs |
| 이사회 평균 재임 기간 | 4yrs |
최근 관리 업데이트
Recent updates
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Oct 04
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Jun 19Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Mar 15Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Nov 16Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Jun 06Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
Feb 09Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Oct 25Design Therapeutics GAAP EPS of -$0.27 misses by $0.02
Aug 08We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate
Jul 02Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Mar 18Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
Dec 03Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation
Aug 18Design Therapeutics expands board of directors
Jun 07Design Therapeutics EPS misses by $0.24
May 10CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$361k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$69m |
| Dec 31 2022 | US$5m | US$338k | -US$63m |
| Sep 30 2022 | n/a | n/a | -US$57m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | US$585k | US$310k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$400k | US$250k | -US$8m |
보상 대 시장: Pratik's total compensation ($USD6.32M) is above average for companies of similar size in the US market ($USD1.48M).
보상과 수익: Pratik's compensation has increased whilst the company is unprofitable.
CEO
Pratik Shah (54 yo)
1.3yrs
테뉴어
US$6,317,780
보상
Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 1.3yrs | US$6.32m | 0.23% $ 675.6k | |
| Chief Operating Officer | 3.8yrs | US$1.28m | 1.44% $ 4.2m | |
| Co-Founder & Scientific Advisor | no data | 데이터 없음 | 13.54% $ 39.9m | |
| Chief Accounting Officer | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| General Counsel | no data | 데이터 없음 | 데이터 없음 | |
| Consulting Chief Medical Officer | 2.8yrs | 데이터 없음 | 0.0084% $ 24.7k | |
| Controller | 4.6yrs | 데이터 없음 | 데이터 없음 |
3.2yrs
평균 재임 기간
54yo
평균 연령
경험이 풍부한 관리: DSGN's management team is considered experienced (3.2 years average tenure).
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 6.9yrs | US$6.32m | 0.23% $ 675.6k | |
| Co-Founder & Scientific Advisor | no data | 데이터 없음 | 13.54% $ 39.9m | |
| Independent Director | 4yrs | US$106.70k | 0.10% $ 299.7k | |
| Independent Director | 5.3yrs | US$228.56k | 0.23% $ 691.7k | |
| Lead Independent Director | 4.8yrs | US$95.70k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$94.20k | 0.042% $ 123.8k | |
| Independent Director | 3.4yrs | US$94.20k | 0.0023% $ 6.8k | |
| Independent Director | 3.8yrs | US$104.20k | 0% $ 0 |
4.0yrs
평균 재임 기간
49yo
평균 연령
경험이 풍부한 이사회: DSGN's board of directors are considered experienced (4 years average tenure).